CKD Strikes 1 in 5 Hospitalized Cirrhosis Patients and Doubles Death Risk
A global study of 7,040 cirrhosis inpatients finds CKD present in 18% of cases, dramatically worsening outcomes including AKI and mortality.
Summary
A large international study involving 127 hospitals and over 7,000 hospitalized cirrhosis patients found that roughly 1 in 5 had chronic kidney disease (CKD). Those with CKD faced far more severe complications: nearly 60% developed acute kidney injury during hospitalization, compared to 27% without CKD. Ascites occurred in 76% of CKD patients versus 61% in those without. Both in-hospital and 30-day post-discharge mortality were significantly higher in the CKD group. Prevalence of CKD was highest in high-income countries, likely reflecting greater rates of metabolic syndrome. The findings highlight the urgent need for proactive kidney monitoring, careful ascites management, and lifestyle modification in cirrhosis patients worldwide.
Detailed Summary
Chronic kidney disease (CKD) is an increasingly recognized but under-addressed complication in patients with liver cirrhosis. Understanding how common it is globally, and what it means for patient survival, has important implications for hepatology practice across all healthcare settings.
This study drew from the CLEARED consortium, a prospective international registry enrolling non-electively admitted cirrhosis patients from 127 sites across multiple World Bank income strata. Of 7,040 inpatients, researchers identified those with CKD (defined as GFR below 60 mL/min/1.73 m² for more than three months) and compared their outcomes to those without.
CKD was present in 18.17% of the global cohort. CKD-positive patients had a median GFR of just 32 mL/min/1.73 m², versus 88 in CKD-negative patients. Acute kidney injury developed in nearly 60% of CKD patients during hospitalization, more than double the rate in those without CKD. Ascites was significantly more prevalent in CKD patients (76.5% vs. 61.1%). High-income countries showed the highest CKD prevalence, tracking with their elevated rates of metabolic syndrome, a key driver of both liver and kidney disease.
Most critically, CKD was independently associated with higher in-hospital mortality and higher 30-day post-discharge mortality, underscoring its role as a major prognostic determinant in admitted cirrhosis patients.
For clinicians, these findings reinforce the need to screen all admitted cirrhosis patients for CKD and to manage ascites meticulously, as it is both a marker and driver of kidney stress. Lifestyle interventions targeting metabolic syndrome — particularly in high-income populations — may help break the liver-kidney disease cycle. A key caveat is that this summary is based on the abstract alone, limiting insight into subgroup analyses and adjusted mortality models.
Key Findings
- 18.17% of 7,040 hospitalized cirrhosis patients globally had CKD, highest in high-income countries.
- CKD patients had a median GFR of 32 vs. 88 mL/min/1.73 m² in non-CKD patients.
- Acute kidney injury occurred in 59.4% of CKD patients vs. 27% in those without CKD.
- Ascites was present in 76.5% of CKD-positive vs. 61.1% of CKD-negative patients.
- CKD was associated with significantly higher in-hospital and 30-day post-discharge mortality.
Methodology
Prospective observational cohort study via the CLEARED consortium, enrolling non-electively admitted cirrhosis patients from 127 sites globally. Patients were stratified by CKD status and World Bank income classification. Data covered demographics, comorbidities, cirrhosis history, hospital course, and outcomes.
Study Limitations
This summary is based on the abstract only, as the full text was not available; details on adjusted analyses, specific subgroups, and confounding variables cannot be assessed. The observational design limits causal inference. Variation in CKD diagnosis and GFR measurement across 127 global sites may introduce inconsistency.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.